Transition to once-weekly growth hormone in paediatric isolated growth hormone deficiency: a real-world experience.

What Was Tested

This observational study looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Who Took Part

According to the abstract, 52 boys were involved.

The age groups tagged for this paper are children and teenagers, both men and women.

At the time of data collection, all 73 patients had completed 6 months of follow-up, while 58 and 27 patients had completed 12 and 18 months, respectively.

Assessments were performed 6 months prior to transition and at 6, 12, and 18 months after initiation of long-acting growth hormone therapy.

How the Study Was Run

Primary outcomes were changes in height standard deviation score (SDS) and height velocity SDS.

Secondary outcomes included body mass index (BMI) SDS, weight SDS, and serum insulin-like growth factor-1 (IGF-1) SDS.

What Was Measured

Topics PubMed links to this paper include Human Growth Hormone, Insulin-Like Growth Factor I, Body Height, Recombinant Proteins, Body Mass Index, Growth Disorders and Dwarfism, Pituitary.

The authors tagged it with the keywords growth hormone deficiency, long-acting growth hormone, real-world outcomes, somatrogon and transition.

What This Means in Plain Language

This is an observational study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 52 boys.

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2026 (European journal of endocrinology), a journal based in England.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.